📊 CAI Key Takeaways
Is Caris Life Sciences, Inc. (CAI) a Good Investment?
Caris Life Sciences demonstrates strong revenue growth (97% YoY) and solid free cash flow generation ($66.9M), indicating operational traction in its medical laboratory services business. However, the company is unprofitable at the net income level (-$68.1M, -8.4% margin) with weak interest coverage (0.8x), suggesting margin expansion challenges and debt servicing risks that must stabilize before a positive recommendation.
Caris Life Sciences shows unusually strong top-line momentum, with revenue up 97.0% year over year and a swing to positive operating income and free cash flow, indicating improving scale economics. The balance sheet is also solid, with very high liquidity and a large cash position, but the company remains net unprofitable and interest coverage is still weak, so execution on sustained margin expansion remains critical.
Why Buy Caris Life Sciences, Inc. Stock? CAI Key Strengths
- Exceptional revenue growth of 97% YoY demonstrates strong market demand for oncology testing services
- Robust free cash flow of $66.9M (8.2% FCF margin) shows the business converts growth into cash despite net losses
- Excellent liquidity position with $796.3M cash and 7.85x current ratio provides significant financial flexibility and runway
- Positive operating cash flow of $83.2M indicates core operations generate cash before working capital and financing activities
- Revenue growth is exceptionally strong at 97.0% YoY, suggesting strong demand and scaling momentum
- Operating profitability and positive free cash flow indicate improving business quality and better cash conversion
- Balance sheet liquidity is strong, with $796.27M in cash and a 7.85x current ratio
CAI Stock Risks: Caris Life Sciences, Inc. Investment Risks
- Persistent net losses (-$68.1M) and negative net margin (-8.4%) indicate business model has not achieved profitability despite rapid scaling
- Weak interest coverage ratio of 0.8x is concerning with $378.4M long-term debt; company cannot cover interest from operating income alone
- Deteriorating EPS trend (-$3.22 diluted) despite revenue growth suggests margin compression and potential dilution from capital raises
- Operating margin of only 5.6% provides minimal buffer; slight revenue decline or cost increase could reverse cash generation
- Net income remains negative, so full earnings profitability has not yet been achieved
- Interest coverage of 0.8x indicates debt servicing remains tight despite positive operating income
- Gross margin data is unavailable, limiting visibility into underlying unit economics and margin durability
Key Metrics to Watch
- Path to net profitability and net margin expansion from current -8.4% level
- Interest coverage ratio improvement above 1.5x to ensure sustainable debt service capability
- Operating margin sustainability and whether economies of scale drive incremental margin improvement as revenue grows
- Cash burn rate and runway given unprofitability; validate $796.3M cash is sufficient to reach breakeven
- Net margin and sustained GAAP net income improvement
- Interest coverage and debt service capacity
Caris Life Sciences, Inc. (CAI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.85x current ratio provides a solid financial cushion.
CAI Profit Margin, ROE & Profitability Analysis
CAI vs Healthcare Sector: How Caris Life Sciences, Inc. Compares
How Caris Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Caris Life Sciences, Inc. Stock Overvalued? CAI Valuation Analysis 2026
Based on fundamental analysis, Caris Life Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Caris Life Sciences, Inc. Balance Sheet: CAI Debt, Cash & Liquidity
CAI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Caris Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-13.24 indicates the company is currently unprofitable.
CAI Revenue Growth, EPS Growth & YoY Performance
CAI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $101.6M | $24.3M | $0.08 |
| Q2 2025 | $100.0M | -$66.2M | $-2.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Caris Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
CAI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Caris Life Sciences, Inc. (CIK: 0002019410)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CAI
What is the AI rating for CAI?
Caris Life Sciences, Inc. (CAI) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CAI's key strengths?
Claude: Exceptional revenue growth of 97% YoY demonstrates strong market demand for oncology testing services. Robust free cash flow of $66.9M (8.2% FCF margin) shows the business converts growth into cash despite net losses. ChatGPT: Revenue growth is exceptionally strong at 97.0% YoY, suggesting strong demand and scaling momentum. Operating profitability and positive free cash flow indicate improving business quality and better cash conversion.
What are the risks of investing in CAI?
Claude: Persistent net losses (-$68.1M) and negative net margin (-8.4%) indicate business model has not achieved profitability despite rapid scaling. Weak interest coverage ratio of 0.8x is concerning with $378.4M long-term debt; company cannot cover interest from operating income alone. ChatGPT: Net income remains negative, so full earnings profitability has not yet been achieved. Interest coverage of 0.8x indicates debt servicing remains tight despite positive operating income.
What is CAI's revenue and growth?
Caris Life Sciences, Inc. reported revenue of $812.0M.
Does CAI pay dividends?
Caris Life Sciences, Inc. does not currently pay dividends.
Where can I find CAI SEC filings?
Official SEC filings for Caris Life Sciences, Inc. (CIK: 0002019410) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CAI's EPS?
Caris Life Sciences, Inc. has a diluted EPS of $-3.22.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CAI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Caris Life Sciences, Inc. has a BUY rating with 69% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CAI stock overvalued or undervalued?
Valuation metrics for CAI: ROE of -11.8% (sector avg: 15%), net margin of -8.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CAI stock in 2026?
Our dual AI analysis gives Caris Life Sciences, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CAI's free cash flow?
Caris Life Sciences, Inc.'s operating cash flow is $83.2M, with capital expenditures of $16.3M. FCF margin is 8.2%.
How does CAI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8.4% (avg: 12%), ROE -11.8% (avg: 15%), current ratio 7.85 (avg: 2).